{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 33,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "appendix_methodology",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a footnote citation for the methodology definitions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/13",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.06,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Both analyses are valid, yet PP best answers the question of what is the effect of receiving the treatment on a group of patients versus the effect of assigning the treatment to a group of patients.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "269b4d89-0937-4289-8ec9-aecc8148900a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Intent to Treat (ITT) and Per Protocol (PP) are both pre-specified analyses within the study. ITT assesses the effect of the treatment on all patients enrolled in the study while PP analysis includes only patients who strictly adhered to the study protocol.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f2ad530-d102-41fc-a41b-8767adf8aa69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1Tripepi G, Chesnaye NC, Dekker FW, Zoccali C, Jager KJ. Intention to treat and per protocol analysis in clinical trials. Nephrology. 2020;25:513–517.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9636597-7cb8-4824-8c18-272ea99e992c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.55,
        "y": 0.22
      },
      "kind": "table",
      "text": "Analysis Pre-defined populations: ITT (N=68), PP (N=62). PrimeC: n=45, n=43. Placebo: n=23, n=19.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59f34544-02a7-4974-9c45-26faa3b7cb7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "PrimeC Phase 2b Study\nITT and PP Pre-specified Analyses",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b16c2cdc-ed83-4663-a7e6-09cef63227c1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "4366de44-285f-47c6-a810-d1c6a8fc086e",
      "evidence": "table/data: Analysis Pre-defined populations: ITT (N=68), PP (N=62). PrimeC: n=45, n=43. Placebo: n=23, n=19.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}